Histoplasma capsulatum var. capsulatum histoplasmosis is the leading cause of acquired immunodeficiency syndrome (AIDS) and death in French Guiana and probably in the Amazon. The diagnosis of this disease requires invasives procedures, laboratory performance, and delays up to several weeks. The Mycotic Diseases Branch of the Centers for Disease Control and Prevention (CDC) has established a rapid, sensitive and specific ELISA test for blood and urine samples that looks interesting in endemic areas, particularly in developing countries. The study aims to measure the proportion of HIV-infected patients hospitalized or in outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum and/or urinary antigen detection tests are positive for Histoplasma capsulatum var. capsulatum.
Study Type
OBSERVATIONAL
Enrollment
727
Pointe-à-Pitre University Hospital
Pointe à Pitre, Guadeloupe, France
Cayenne General Hospital
Cayenne, Guyane, France
Western French Guiana Hospital
Saint-Laurent-du-Maroni, Guyane, France
Fort-de-France University Hospital
Fort-de-France, Martinique, France
's Lands Hospital
Paramaribo, Paramaribo District, Suriname
Academisch Ziekenhuis Paramaribo Hospital
Paramaribo, Paramaribo District, Suriname
Diakonessenhuis hospital
Paramaribo, Paramaribo District, Suriname
Proportion of HIV-infected patients hospitalized or in outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum and/or urinary antigen detection tests are positive for Histoplasma capsulatum var. capsulatum.
Time frame: At the time of inclusion (baseline)
Sensitivity of the ELISA test on urine and blood specimens
Time frame: At the time of inclusion (baseline)
Sensibility of the ELISA test on urine and blood specimens
Time frame: At the time of inclusion (baseline)
Negative predictive value of the ELISA test on urine and blood specimens
Time frame: At the time of inclusion (baseline)
Comparison of the distribution of Histoplasma antigen concentrations in urine and serum specimens according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum
Time frame: At the time of inclusion (baseline)
Comparison of the socio-demographic, clinical, paraclinical and therapeutic characteristics according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum
Time frame: 30 days or 90 days after inclusion
Comparison of the factors for environmental exposure to Histoplasma capsulatum var capsulatum between patients with a positive ELISA test and/or fungal culture for histoplasmosis and those who tested negative for histoplasmosis
Time frame: At the time of inclusion
Frequency of histoplasmosis compared to the other main diagnoses according to three sets of comparisons: positive ELISA test and positive fungal culture; positive ELISA test and negative fungal culture; negative ELISA test and positive fungal culture
Time frame: 90 days after inclusion
Comparison of the socio-demographic, clinical, paraclinical, therapeutic and survival outcome characteristics of cases of histoplasmosis compared to those who tested negative for histoplasmosis
Time frame: 90 days after inclusion
Identify the prognostic factors for short-term unfavourable progression of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum confirmed by ELISA test and/or by fungal culture
Time frame: 30 days and 90 days after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.